Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited announces a change in its corporate team, with Mr. Peter Vaughan stepping in as the interim Company Secretary effective immediately, replacing Mr. Darren Keamy who has served since 2005. The company is in search of a permanent replacement expected by August 6, 2024. Clinuvel, a global specialty pharmaceutical group, is known for its innovative treatments including SCENESSE®, the first systemic photoprotective drug.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
